skip to main content

Enthesitis-related arthritis — SCE Rheumatology MCQ

Instant feedback + full explanation. One question, done properly.

HardPaediatric RheumatologyEnthesitis-related arthritisSCE Rheumatology

A patient labelled as difficult-to-treat RA has been recorded as failing three biologic mechanisms. Pharmacy records show long gaps in collection, adalimumab concentrations were repeatedly undetectable without anti-drug antibodies, and examination now shows six swollen joints. What should precede a fourth mechanism switch?

Educational content. Not a substitute for clinical judgement or local policy.

Reveal the answer and explanation

Correct answer: E — Address adherence barriers, then reassess inflammation after reliable drug exposure

Explanation lettering: E = shown as B · B = shown as C · C = shown as E

C is correct. EULAR difficult-to-treat guidance requires verification of inflammation and adherence before another mechanism is declared ineffective. Undetectable drug without antibodies plus dispensing gaps indicates non-exposure, so barriers and shared decisions come first. A creates another uninterpretable failure. B has no validated selection role. D substitutes chronic toxicity for a solvable delivery problem. E ignores objective synovitis.

Reference: EULAR points to consider for difficult-to-treat rheumatoid arthritis: https://ard.bmj.com/content/81/1/20